A phase 2, open‐label, randomized, multiple dose study evaluating Inarigivir in treatment‐naïve patients with chronic hepatitis B

Man‐Fung Yuen,C. Y. Chen,C. J. Liu,W. J. Jeng,M. Elkhashab,C. S. Coffin,W. Kim, S. Greenbloom, A. Ramji,Y. S. Lim,Yoon Jun Kim,Scott K. Fung,D. J. Kim,Jeong Won Jang,K. S. Lee,R. P. Iyer, C. Macfarlane,K. Jackson,S. Locarnini,H. L. Y. Chan,N. H. Afdhal

Liver International（2022）

引用 8|浏览14

暂无评分

摘要

Twelve-week Inarigivir up to 200 mg dose was associated with a reduction of HBV DNA, HBV RNA and antigen levels. A trend for greater HBsAg reduction was observed in Inarigivir pre-treated patients after switching to tenofovir.

查看译文

关键词

HBV DNA suppression,HBsAg level,Inarigivir,retinoic acid-inducible gene 1,tenofovir

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要